Follow
'Thus, identifying the subset of patients for whom public neoantigens are relevant targets is a major challenge. Nevertheless, the ability provided by the expansion of standard-of-care next-generation sequencing to screen patients affords the opportunity for off-the-shelf precision immunotherapies against public neoantigens that would be broadly applicable to many patients and would have tremendous advantages in scalability relative to targeting private neoantigens'
#Immunology #Immunotherapy #TumorImmunology
